These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34225556)

  • 1. Ceftriaxone and methicillin-susceptible
    Telles JP; Leme RCP; Campos ML; Ito C; Bail L; Nogueira KDS; Tuon FF
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1039-1048. PubMed ID: 34225556
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.
    Zelenitsky SA; Beahm NP; Iacovides H; Ariano RE; Zhanel G
    J Antimicrob Chemother; 2018 Jul; 73(7):1888-1894. PubMed ID: 29635472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
    Housman ST; Sutherland CA; Nicolau DP
    Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus: is it a viable treatment option?
    Heffernan AJ; Sime FB; Lim SMS; Adiraju S; Wallis SC; Lipman J; Grant GD; Roberts JA
    Int J Antimicrob Agents; 2022 Mar; 59(3):106537. PubMed ID: 35093539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
    Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Gern BH; Greninger AL; Weissman SJ; Stapp JR; Tao Y; Qin X
    Ann Clin Microbiol Antimicrob; 2018 Feb; 17(1):5. PubMed ID: 29463249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
    Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftriaxone susceptibility of oxacillin-susceptible Staphylococcus aureus from patients with prosthetic joint infection.
    Greenwood-Quaintance KE; Kohner P; Osmon DR; Virk A; Patel R
    Diagn Microbiol Infect Dis; 2015 Jun; 82(2):177-8. PubMed ID: 25842182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of antimicrobial susceptibility patterns in Staphylococcus aureus strains recovered from patients at two main health facilities in Kabul, Afghanistan.
    Naimi HM; Rasekh H; Noori AZ; Bahaduri MA
    BMC Infect Dis; 2017 Nov; 17(1):737. PubMed ID: 29187146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of cefazolin in critically ill children infected with methicillin-sensitive Staphylococcus aureus.
    Salvador E; Oualha M; Bille E; Beranger A; Moulin F; Benaboud S; Boujaafar S; Gana I; Urien S; Zheng Y; Toubiana J; Briand C; Bustarret O; Geslain G; Renolleau S; Treluyer JM; Hirt D
    Clin Microbiol Infect; 2021 Mar; 27(3):413-419. PubMed ID: 32360445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic analysis of ceftriaxone, gatifloxacin,and levofloxacin against Streptococcus pneumoniae with the use of Monte Carlo simulation.
    Frei CR; Burgess DS
    Pharmacotherapy; 2005 Sep; 25(9):1161-7. PubMed ID: 16164390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.
    Rybak MJ; Houlihan HH; Mercier RC; Kaatz GW
    Antimicrob Agents Chemother; 1997 Jun; 41(6):1359-63. PubMed ID: 9174199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
    Lepak AJ; Marchillo K; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
    Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
    Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal dosing regimen of oral administration of dicloxacillin using Monte Carlo simulation.
    Yu W; Ji J; Xiao T; Ying C; Fang J; Shen P; Xiao Y
    Drug Des Devel Ther; 2017; 11():1951-1956. PubMed ID: 28721014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
    Sader HS; Farrell DJ; Flamm RK; Jones RN
    Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Graninger W; Leitha T; Havel M; Georgopoulos A
    Infection; 1984; 12(4):293-5. PubMed ID: 6092279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ceftriaxone Etest non-susceptible methicillin susceptible Staphylococcus aureus time-kill responses.
    Bremmer DN; Balada-Llasat JM; Goff DA; Bauer KA
    Diagn Microbiol Infect Dis; 2017 Jun; 88(2):192-194. PubMed ID: 28291629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosfomycin plus β-Lactams as Synergistic Bactericidal Combinations for Experimental Endocarditis Due to Methicillin-Resistant and Glycopeptide-Intermediate Staphylococcus aureus.
    del Río A; García-de-la-Mària C; Entenza JM; Gasch O; Armero Y; Soy D; Mestres CA; Pericás JM; Falces C; Ninot S; Almela M; Cervera C; Gatell JM; Moreno A; Moreillon P; Marco F; Miró JM;
    Antimicrob Agents Chemother; 2016 Jan; 60(1):478-86. PubMed ID: 26525803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.